Ascendis Pharma A (ASND) Non-Current Receivables: 2019-2024
- Ascendis Pharma A's Non-Current Receivables rose 8.19% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.5 million, marking a year-over-year increase of 8.19%. This contributed to the annual value of $2.5 million for FY2024, which is 9.58% up from last year.
- As of Q4 2024, Ascendis Pharma A's Non-Current Receivables stood at $2.5 million, which was up 8.19% from $2.3 million recorded in Q4 2023.
- Over the past 5 years, Ascendis Pharma A's Non-Current Receivables peaked at $2.5 million during Q4 2024, and registered a low of $1.6 million during Q4 2020.
- Moreover, its 3-year median value for Non-Current Receivables was $2.3 million (2023), whereas its average is $2.2 million.
- Per our database at Business Quant, Ascendis Pharma A's Non-Current Receivables rose by 26.16% in 2021 and then declined by 5.29% in 2022.
- Quarterly analysis of 5 years shows Ascendis Pharma A's Non-Current Receivables stood at $1.6 million in 2020, then increased by 26.16% to $2.1 million in 2021, then decreased by 5.29% to $2.0 million in 2022, then increased by 16.83% to $2.3 million in 2023, then grew by 8.19% to $2.5 million in 2024.
- Its last three reported values are $2.5 million in Q4 2024, $2.3 million for Q4 2023, and $2.0 million during Q4 2022.
